Mechanistic Target of Rapamycin Complex 2
"Mechanistic Target of Rapamycin Complex 2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A multiprotein complex consisting of MTOR KINASE; MLST8 PROTEIN; rapamycin-insensitive companion of mTOR protein (RICTOR PROTEIN); and PRR5 (proline-rich protein 5). Like MTORC1, it also regulates cell growth and proliferation in response to growth factors but may not be as sensitive to nutrient availability and is insensitive to SIROLIMUS. In contrast to MTORC1, it can regulate the ACTIN CYTOSKELETON through RHO GTPASES to promote the formation of STRESS FIBERS. The mTORC2 complex also plays a critical role in AKT1 PROTEIN KINASE phosphorylation and activation.
| Descriptor ID |
D000076225
|
| MeSH Number(s) |
D05.500.356 D08.811.913.696.620.682.700.931.750 D12.776.476.925.750
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Mechanistic Target of Rapamycin Complex 2".
Below are MeSH descriptors whose meaning is more specific than "Mechanistic Target of Rapamycin Complex 2".
This graph shows the total number of publications written about "Mechanistic Target of Rapamycin Complex 2" by people in this website by year, and whether "Mechanistic Target of Rapamycin Complex 2" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2012 | 0 | 2 | 2 |
| 2013 | 0 | 2 | 2 |
| 2015 | 0 | 4 | 4 |
| 2016 | 0 | 2 | 2 |
| 2018 | 1 | 0 | 1 |
| 2019 | 2 | 0 | 2 |
| 2020 | 1 | 2 | 3 |
| 2023 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Mechanistic Target of Rapamycin Complex 2" by people in Profiles.
-
Targeted suppression of mTORC2 reduces seizures across models of epilepsy. Nat Commun. 2023 11 14; 14(1):7364.
-
Dapagliflozin and Ticagrelor Have Additive Effects on the Attenuation of the Activation of the NLRP3 Inflammasome and the Progression of Diabetic Cardiomyopathy: an AMPK-mTOR Interplay. Cardiovasc Drugs Ther. 2020 08; 34(4):443-461.
-
HEM1 deficiency disrupts mTORC2 and F-actin control in inherited immunodysregulatory disease. Science. 2020 07 10; 369(6500):202-207.
-
Preclinical and Dose-Finding Phase I Trial Results of Combined Treatment with a TORC1/2 Inhibitor (TAK-228) and Aurora A Kinase Inhibitor (Alisertib) in Solid Tumors. Clin Cancer Res. 2020 09 01; 26(17):4633-4642.
-
Therapeutic inhibition of mTORC2 rescues the behavioral and neurophysiological abnormalities associated with Pten-deficiency. Nat Med. 2019 11; 25(11):1684-1690.
-
Disruption of the Scaffolding Function of mLST8 Selectively Inhibits mTORC2 Assembly and Function and Suppresses mTORC2-Dependent Tumor Growth In Vivo. Cancer Res. 2019 07 01; 79(13):3178-3184.
-
mTORC2, but not mTORC1, is required for hippocampal mGluR-LTD and associated behaviors. Nat Neurosci. 2018 06; 21(6):799-802.
-
mTORC1 and mTORC2 Kinase Signaling and Glucose Metabolism Drive Follicular Helper T Cell Differentiation. Immunity. 2016 09 20; 45(3):540-554.
-
Pulsatile delivery of a leucine supplement during long-term continuous enteral feeding enhances lean growth in term neonatal pigs. Am J Physiol Endocrinol Metab. 2016 04 15; 310(8):E699-E713.
-
period-Regulated Feeding Behavior and TOR Signaling Modulate Survival of Infection. Curr Biol. 2016 Jan 25; 26(2):184-194.